Biogen (BIIB) Gains 5% on Strong Q4 Results, Promising Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Biogen (BIIB) Pushes Higher Following EPS
January 27, 2016 11:55 AM ESTBiogen (NASDAQ: BIIB) is pushing to the highs of the session following strong earnings and a solid outlook. Shares are now up 7.9%
... MoreBiogen (BIIB) Tops Q4 EPS by 42c; Guides In-Line
January 27, 2016 7:16 AM ESTBiogen (NASDAQ: BIIB) reported Q4 EPS of $4.50, $0.42 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.84 billion versus the consensus estimate of $2.71 billion.
GUIDANCE:
Biogen sees FY2016 EPS of $18.30-$18.60, versus the consensus of $18.45. Biogen sees FY2016 revenue of $11.1-11.3 billion, versus the consensus of $11.29 billion.
We saw solid performance in our industry leading multiple sclerosis portfolio and strong... More
